NorthSea Therapeutics B.V.   Report issue

For profit Phase 1 Phase 2
Founded: Naarden Netherlands (2017)

Organization Overview

First Clinical Trial
2018
NCT03577275
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

NorthSea Therapeutics B.V.

Active Ingredients

Drugs in Phase 2 Trials (1)

icosabutate (2 trials)

Drugs in Phase 1 Trials (2)

moxifloxacin (avelox) (1 trial)

nst-1024 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyslipidemias (Phase 1)

Fatty Liver (Phase 2)

Hypertriglyceridemia (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3